Since mutant KRAS was long considered undruggable, the development and the clinical success of G12C inhibitors pave the way for the development of non-G12C mutant KRAS inhibitors, opening the door for a new era of target therapies aiming at the most frequently mutated human oncogene in various cancers including the lung adenocarcinoma. This evidence concerns the gene KRAS and cancer.